CELLECTIS S.A.

Company Overview

Cellectis is a clinical-stage biotechnological company that uses core proprietary technologies to develop products based on gene editing. Allogeneic Chimeric Antigen Receptor T-cells or UCART, are product candidates in immunooncology and gene-edited hematopoietic stem and progenitor cells or HSPC, are product candidates in other therapeutic indications. The company has submitted around 54 additional patent application families of CAR T-cell technology since 2012. Patent applications for the production of allogeneic immune cells and CAR design, including multi-subunit and conditional expression CARs, are included in this portfolio.

The company is creating several product candidates for advanced hematologic malignancies. Universal CAR T-cells (UCARTs), their primary immuno-oncology product prospects, are allogeneic CAR T-cells designed to be utilized as an “off-the-shelf” therapy. Every UCART product candidate is made to target a particular antigen that is expressed on tumor cells and has unique engineering features, such as the ability to suppress alloreactivity and work with certain treatment plans that cancer patients could follow. The first therapeutic product line that Cellectis is creating using its gene-editing platform to meet unmet cancer medical needs is called UCART. The first internal pipeline is concentrated in the hematologic cancer field, aiming to treat conditions including NHL, AML and ALL with significant unmet requirements.

Financial Highlights (FY 2024)

Company's Business Segments

• Collaboration Agreements : This segment of the company payments, services and royalties on licensed technologies and collaboration agreements.
• Licenses : This segment of the company is deriving revenue from third party companies for licensing them the Patents, Products developed by cellectis.
• Products and Services : This segment includes products like Allogeneic CAR-T Cell Pipeline for B-Cell Acute Lymphoblastic Leukemia (B-ALL), Non-Hodgkin Lymphoma (NHL), Acute Myeloid Leukemia (AML).